Summary
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart OTCMKTS: VXRT held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors, ratified its auditor and rejected the company's non-binding advisory proposal on executive compensation.
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 316,201 | $1.98M | $158,954.24 | -$1.82M | -91.98% |
 Rajiv Shah KINGSWOOD WEALTH ADVISORS, LLC | 10,005 | $6,053 | $5,402.7 | -$650.3 | -10.74% |
Vaxart Inc. (VXRT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vaxart Inc. ever had a stock split?
Vaxart Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven Lo CEO | OTC PINK Exchange | 92243A200 CUSIP |
| US Country | 65 Employees | 14 Feb 2018 Last Dividend | 14 Feb 2018 Last Split | 12 Feb 2018 IPO Date |
Overview
Vaxart, Inc. is a clinical-stage biotechnology company that specializes in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's innovative approach aims to deliver vaccines in tablet form, offering a convenient and needle-free method of vaccination against various infectious diseases. Headquartered in South San Francisco, California, Vaxart is at the forefront of developing a new generation of oral vaccines to address a range of infections, including norovirus, influenza, respiratory syncytial virus (RSV), coronavirus, and human papillomavirus (HPV) related conditions.
Products and Services
- Norovirus Vaccine:
Vaxart is advancing an oral tablet vaccine against the norovirus, targeting the GI.1 and GII.4 strains, which are the most common causes of norovirus outbreaks. Currently, this vaccine candidate is in a Phase Ib clinical trial. The development of an oral norovirus vaccine represents a significant step forward in preventing a leading cause of gastroenteritis worldwide.
- Seasonal Influenza Vaccine:
The company's seasonal influenza vaccine candidate has reached a Phase II clinical trial phase. It is designed to protect against H1 influenza infection. An oral influenza vaccine could greatly improve vaccination rates by eliminating the need for injections, making it easier and more appealing for people to get vaccinated against seasonal flu.
- Respiratory Syncytial Virus (RSV) Vaccine:
Another important area of Vaxart's research is the development of a vaccine for respiratory syncytial virus (RSV). RSV is a major cause of respiratory illness in infants and elderly adults. The company's approach to an oral RSV vaccine could transform the prevention of this common respiratory infection, especially among the most vulnerable populations.
- Coronavirus Vaccine:
Responding to the global need for more effective and accessible COVID-19 vaccines, Vaxart's coronavirus vaccine candidate is in a Phase II clinical trial for the treatment of SARS-CoV-2 infection. This oral vaccine, if successful, could offer a breakthrough in managing and preventing COVID-19, with the ease of distribution and administration being critical advantages over injectable vaccines.
- Therapeutic Vaccines for Cervical Cancer and Dysplasia:
Vaxart is also developing therapeutic vaccines aimed at treating cervical cancer and dysplasia caused by human papillomavirus (HPV). These vaccines are part of the company's efforts to extend its oral vaccine platform to not just prevent viral infections but also to treat conditions caused by viruses, marking an exciting direction in the company's research endeavors.
